Ardelyx, Inc. ARDX

Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the YearWALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of

200-Page Report Tracks Unicycive's PDUFA-Bound Oxylanthanum Carbonate and Ardelyx's Tenapanor as a Market Built on Aging Binders Shifts Toward Novel MechanismsDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Hyperphosphatemia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The "Hyperphosphatemia - Market Insights, Epidemiology and Market Forecast - 2036" report provides a comprehensive assessment of the hyperphosphatemia market acro

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences: Citi's 2026 Biopharma Back to School ConferenceLocation: New York, NYInvestor Meetings: Wednesday, September 9 2026 Cantor Global Healthcare ConferenceLocati

Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts. See our latest analysis for Ardelyx. The guidance cut and lowered expectations for IBSRELA have come alongside a sharp reset in Ardelyx’s share price, with the stock down 23.43% on a 30 day share price return basis and 36.33% on a 1 year total shareholder return...

Valeris, an integrated commercialization partner helping life sciences companies connect market access, patient services, and commercial strategy, today announced the appointment of Lauren Cole as Chief Strategy Officer, reporting to Chief Commercial Officer Scott Filosi. The appointment reflects Valeris' continued investment in growth and innovation, with the patient kept at the center of every strategic decision.

In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...

Ardelyx (ARDX) is back in focus after reporting record Q2 2026 revenue driven by IBSRELA and XPHOZAH, while missing earnings estimates and trimming IBSRELA guidance because of payer related hurdles. See our latest analysis for Ardelyx. Despite the record Q2 revenue, Ardelyx’s recent earnings miss and reduced IBSRELA guidance appear to be weighing on sentiment, with the share price down 9.48% over 30 days and 20.81% year to date, even though the 5 year total shareholder return of 220.39%...

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

Ardelyx Inc (ARDX) delivers 31% revenue growth in Q2 2026 while navigating payer-imposed challenges that led to a lowered Ibsrela outlook and withdrawal of Xphozah guidance.

Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents and investments as of June 30, 2026 Revising FY 2026 and long-term guidance Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARD

Nephrologists say they would nearly triple Xphozah use without access barriers, but Spherix chart data reveal that physicians substantially overestimate both phosphorus control and combination therapy use among their patients.Exton, PA, July 29, 2026 (GLOBE NEWSWIRE) -- Access, not efficacy, stands between Ardelyx's Xphozah® (tenapanor) and a materially larger share of the dialysis hyperphosphatemia market, according to new findings from Spherix Global Insights' RealTime Dynamix™: Dialysis (US),

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business